« Major Brain Trauma May Have Caused Football Player's Suicide | Main | Tragic Limo Accident Spurs Regulatory Bill »
Neuren Pharmaceuticals Ltd has successfully completed a Phase 1 safety and tolerability trial of its second lead candidate, NNZ-2566, which is being developed to treat traumatic brain injury (TBI). The results from the study
were referred to the independent Data Safety Monitoring Committee for review who confirmed the safety profile of the drug.
Contact Us
1-888-895-2080
Burg Simpson Eldredge Hersh & Jardine, P.C. is a law firm serving the Rocky Mountain Region. The firm has offices in Denver, Colorado, Cody, WY, Cincinnati, Ohio, and Phoenix, AZ. The Firm is responsible for the content on the website, this information is not to be interpreted as providing legal services, nor as proposing any form of legal advice.
